Loading...

Affimed N.V.

AFMDQPNK
Healthcare
Biotechnology
$0.00
$0.00(0.00%)
U.S. Market opens in 56h 0m

Affimed N.V. Fundamental Analysis

Affimed N.V. (AFMDQ) shows weak financial fundamentals with a PE ratio of -0.00, profit margin of -12.80%, and ROE of -1.01%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position1626372.29%
PEG Ratio-0.00
Current Ratio3.25

Areas of Concern

ROE-1.01%
Operating Margin-12.89%
We analyze AFMDQ's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1306.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1306.9/100

We analyze AFMDQ's fundamental strength across five key dimensions:

Efficiency Score

Weak

AFMDQ struggles to generate sufficient returns from assets.

ROA > 10%
-1.09%

Valuation Score

Excellent

AFMDQ trades at attractive valuation levels.

PE < 25
-0.00
PEG Ratio < 2
-0.00

Growth Score

Weak

AFMDQ faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

AFMDQ maintains a strong and stable balance sheet.

Debt/Equity < 1
0.33
Current Ratio > 1
3.25

Profitability Score

Weak

AFMDQ struggles to sustain strong margins.

ROE > 15%
-100.55%
Net Margin ≥ 15%
-12.80%
Positive Free Cash Flow
No

Key Financial Metrics

Is AFMDQ Expensive or Cheap?

P/E Ratio

AFMDQ trades at -0.00 times earnings. This suggests potential undervaluation.

-0.00

PEG Ratio

When adjusting for growth, AFMDQ's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Affimed N.V. at 0.00 times its book value. This may indicate undervaluation.

0.00

EV/EBITDA

Enterprise value stands at -0.19 times EBITDA. This is generally considered low.

-0.19

How Well Does AFMDQ Make Money?

Net Profit Margin

For every $100 in sales, Affimed N.V. keeps $-12.80 as profit after all expenses.

-12.80%

Operating Margin

Core operations generate -12.89 in profit for every $100 in revenue, before interest and taxes.

-12.89%

ROE

Management delivers $-1.01 in profit for every $100 of shareholder equity.

-1.01%

ROA

Affimed N.V. generates $-1.09 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.09%

Following the Money - Real Cash Generation

Operating Cash Flow

Affimed N.V. generates limited operating cash flow of $-120.99M, signaling weaker underlying cash strength.

$-120.99M

Free Cash Flow

Affimed N.V. generates weak or negative free cash flow of $-125.08M, restricting financial flexibility.

$-125.08M

FCF Per Share

Each share generates $-7.63 in free cash annually.

$-7.63

FCF Yield

AFMDQ converts -27315.28% of its market value into free cash.

-27315.28%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.00

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.00

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.001

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.33

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.25

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.01

vs 25 benchmark

ROA

Return on assets percentage

-1.09

vs 25 benchmark

ROCE

Return on capital employed

-1.50

vs 25 benchmark

How AFMDQ Stacks Against Its Sector Peers

MetricAFMDQ ValueSector AveragePerformance
P/E Ratio-0.0029.94 Better (Cheaper)
ROE-100.55%738.00% Weak
Net Margin-1280.22%-575975.00% (disorted) Weak
Debt/Equity0.330.44 Strong (Low Leverage)
Current Ratio3.254.49 Strong Liquidity
ROA-109.04%-15756.00% (disorted) Weak

AFMDQ outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Affimed N.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ